search results for 
Logo

Sales

In 2013, we increased Group sales by 8% in constant currency and by 5% at actual rates to €20,331 million (2012: €19,290 million).

The chart shows the various influences on Fresenius’ Group sales.

In 2013, changes in the product mix mainly had an effect at Fresenius Kabi because of restrictions in the use of blood volume substitutes. Price influences had an effect at Fresenius Medical Care due to budget cuts in the United States, and at Fresenius Kabi due to significant price cuts in China. In 2014, we expect no significant effects from changes in product mix. However, we expect pricing effects for Fresenius Medical Care and Fresenius Kabi.

Sales growth by region was as follows:

The most important regions in the Group are North America and Europe, contributing 42% and 40% of total sales, followed by Asia-Pacific with 10%, and Latin America and Africa with 6% and 2%, respectively. Germany contributed 21% to Group sales.

In North America, organic sales growth was 4%. In constant currency, sales increased by 9%. In Europe, organic sales growth was 3% (6% in constant currency). In the Asia-Pacific region, organic sales growth was 4% (7% in constant currency). Excellent organic sales growth was achieved in Latin America with 13% and in Africa with 23%. In these regions, sales growth in constant currency was 16% and 24%, respectively.

Sales growth in the business segments was as follows:

  • Fresenius Medical Care achieved sales of €11,000 million in 2013 (2012: €10,741 million). Organic sales growth was 5%, while acquisitions contributed 2%. Divestitures reduced sales by 1%. Currency translation had a negative effect of 4%.
  • Fresenius Kabi increased sales by 10% to €4,996 million (2012: €4,539 million). The company achieved organic sales growth of 5%. Acquisitions contributed 10% to sales growth. Divestitures reduced sales by 1%. Currency translation had a negative effect of 4%. Ongoing supply constraints at competitors and product launches again had a positive effect in the United States. Significant price cuts in China and restrictions in the use of blood volume substitutes had an adverse effect.
  • Fresenius Helios increased sales by 6% to €3,393 million (2012: €3,200 million). An increase in admissions and price increases for hospital services contributed to organic sales growth of 3%. Acquisitions contributed 4% to growth. Divestitures reduced sales growth by 1%.
  • Fresenius Vamed increased sales by 21% to €1,020 million (2012: €846 million). Organic sales growth was 13%. Acquisitions contributed 8% to sales growth. Sales in the project business were €583 million (2012: €506 million). Sales in the service business grew strongly by 29% to €437 million, primarily due to acquisitions (2012: €340 million). Order intake in the project business again developed well; it increased by 13% to €744 million (2012: €657 million). Fresenius Vamed increased its order backlog by 15% to €1,139 million (December 31, 2012: €987 million). Fresenius Vamed is the only business segment within the Fresenius Group whose business is significantly determined by order intake and order backlog.

SALES BY REGION


€ in millions20132012ChangeOrganic sales growthCurrency translation effectsAcquisitions / divestitures% of total sales
North America8,6208,1446%4%-3%5%42%
Europe8,2167,7975%3%-1%3%40%
Asia-Pacific1,9451,8992%4%-5%3%10%
Latin America1,1741,1264%13%-12%3%6%
Africa37632416%23%-8%1%2%
Total20,33119,2905%4%-3%4%100%

€ in millions20132012ChangeOrganic sales growthCurrency translation effectsAcquisitions / divestitures% of total sales
North America8,6208,1446%4%-3%5%42%
Europe8,2167,7975%3%-1%3%40%
Asia-Pacific1,9451,8992%4%-5%3%10%
Latin America1,1741,1264%13%-12%3%6%
Africa37632416%23%-8%1%2%
Total20,33119,2905%4%-3%4%100%

SALES BY BUSINESS SEGMENT


€ in millions20132012ChangeOrganic sales growthCurrency translation effectsAcquisitions / divestitures% of total sales
Fresenius Medical Care11,00010,7412%5%-4%1%54%
Fresenius Kabi4,9964,53910%5%-4%9%24%
Fresenius Helios3,3933,2006%3%0%3%17%
Fresenius Vamed1,02084621%13%0%8%5%

€ in millions20132012ChangeOrganic sales growthCurrency translation effectsAcquisitions / divestitures% of total sales
Fresenius Medical Care11,00010,7412%5%-4%1%54%
Fresenius Kabi4,9964,53910%5%-4%9%24%
Fresenius Helios3,3933,2006%3%0%3%17%
Fresenius Vamed1,02084621%13%0%8%5%

ORDER INTAKE AND ORDER BACKLOG − FRESENIUS VAMED


€ in millions20132012201120102009
Order intake744657604625539
Order backlog (December 31)1,139987845801679

€ in millions20132012201120102009
Order intake744657604625539
Order backlog (December 31)1,139987845801679

Continue reading:
Earnings structure

QUICKFINDER

History

Tools